Intensity Therapeutics, a Phase 1 biotech developing intratumoral injection treatments for cancer, filed on Thursday with the SEC to raise up to $17 million in an initial public offering.
Intensity Therapeutics claims to have identified a constraint in existing intratumoral cancer treatment approaches, which is that the tumor's lipophilic, high fat, pressurized microenvironment does not effectively absorb water-based products. The company's lead product candidate, INT230-6, consists of two proven anti-cancer cytotoxic agents, cisplatin and vinblastine sulfate, mixed with the amphiphilic molecule (SHAO), to aid bioavailability. The company entered a Phase 1/2 trial in Canada in 2017 in patients with refractory and metastatic cancers which is still ongoing.
The Westport, CT-based company was founded in 2012 and booked n/a in sales for the 12 months ended . It plans to list on the Nasdaq under the symbol INTS. Intensity Therapeutics filed confidentially on September 20, 2021. A.G.P., and Brookline Capital Markets are the joint bookrunners on the deal. No pricing terms were disclosed.
